Can a zoledronic acid infusion be administered to a patient who has refused kyphoplasty or any spine surgery?

Yes, zoledronic acid infusion can and should be given regardless of whether the patient undergoes spine surgery

Zoledronic acid is indicated for bone disease management in multiple myeloma and bone metastases independent of any surgical intervention. The decision to use bisphosphonates is based on the presence of bone disease, not on whether surgical procedures are performed 1, 2, 3.

Indications for Zoledronic Acid

Zoledronic acid is recommended for:

• Multiple myeloma patients with osteolytic bone disease at diagnosis, given monthly in addition to myeloma-directed therapy 1, 2
• Metastatic bone lesions from solid tumors at 4 mg infused over at least 15 minutes every 3-4 weeks 3
• Hypercalcemia of malignancy 3

The FDA-approved indication specifically states it is for "patients with multiple myeloma and metastatic bone lesions from solid tumors" with no requirement for surgical intervention 3.

Relationship to Surgical Procedures

Surgery (including kyphoplasty) and bisphosphonates serve different therapeutic purposes:

• Kyphoplasty addresses mechanical instability and refractory pain from vertebral compression fractures 1, 2
• Zoledronic acid treats the underlying bone disease by reducing skeletal-related events (pathologic fractures, need for radiation, spinal cord compression) and preventing disease progression 1, 2, 4

The most recent guidelines explicitly state that balloon kyphoplasty "should be considered for symptomatic vertebral compression fractures with refractory pain" 1, while separately recommending that "antiresorptive agents should be given in addition to myeloma-directed therapy in all patients with MM and osteolytic disease at diagnosis" 1. These are parallel, not sequential or dependent recommendations.

Treatment Algorithm

For patients refusing surgery:

1. Initiate zoledronic acid if bone disease is present on imaging (lytic lesions, compression fractures, or osteopenia) 1, 2, 4

2. Dosing: 4 mg IV over 15 minutes every 3-4 weeks (monthly) 1, 2, 3

3. Duration:

   • At least 12 months, up to 48 months for patients achieving complete or very good partial response 1
   • At least 4 years for patients with suboptimal response (partial response or less) 1, 2

4. Mandatory supplementation: Calcium (500-1500 mg daily) and vitamin D (400-800 IU daily) 1, 2, 3

5. Monitoring requirements:

   • Serum creatinine before each dose 3
   • Withhold if creatinine clearance <30-35 mL/min 3
   • Dose reduction for creatinine clearance 30-60 mL/min 3
   • Dental examination before initiating therapy to reduce osteonecrosis of jaw risk 1, 2, 4

Important Caveats

Renal function is the primary contraindication, not surgical status. Zoledronic acid requires adequate renal function (creatinine clearance >30-35 mL/min) 3. In severe renal impairment, denosumab is an alternative, though it carries higher hypocalcemia risk 1, 2.

The 2025 EHA-EMN guidelines (the most recent and highest quality evidence) make no mention of surgery as a prerequisite for bisphosphonate therapy 1. Surgery is listed as a separate intervention for specific complications (long-bone fractures, spinal cord compression, vertebral instability) 1.

Pain management: If the patient has refractory pain from vertebral compression fractures, low-dose radiotherapy (up to 30 Gy) can be used as palliative treatment as an alternative to kyphoplasty 1, 2.